The startup operates a brain health diagnostics tool that compiles a databank of clinical data and radiology for neurological disorders. Its services include segmentation and volumetric analysis reports for clinical users, along with research support for imaging projects in pediatric epilepsy and dementia.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Radiologists face increasing workloads and potential for burnout, while also needing to ensure accurate and timely diagnoses of neurological disorders. Manual segmentation and volumetric analysis of brain structures from medical images is time-consuming and prone to human error.
Solution
InMed AI Studio offers a suite of FDA-cleared, AI-powered tools designed to automate and enhance medical image analysis for various clinical applications. Their Neuroshield products provide automated brain volumetry and lesion detection on MR and CT scans, delivering contextually relevant reports and actionable insights. Neuroshield MR provides volumetric analysis of over 30 brain structures with ethnicity-based reference ranges, while Neuroshield CT-TBI prioritizes head CT scans with pathologies like bleeds and fractures, alerting clinical teams to critical cases. InMed's Oncoshield assists in the early detection and monitoring of liver and pancreatic lesions on CT scans, and Vivoshield analyzes whole-body MRI data to provide insights into body composition.
Target Audience
The primary target audience includes radiologists, neurologists, oncologists, and other healthcare professionals who require accurate and efficient medical image analysis for diagnosis, treatment planning, and monitoring of neurological disorders, traumatic brain injury, cancer, and body composition.
Features
- AI-powered segmentation and volumetric analysis of brain structures from MR and CT images
- Automated detection of lesions, bleeds, fractures, and midline shift
- FDA-cleared for clinical use
- Provides ethnicity-based reference ranges for personalized medicine
- Generates contextually relevant reports with actionable insights
- Integrates with PACS/RIS systems and modality consoles
- Available for cloud and on-premise deployment
- Supports longitudinal tracking of disease progression